Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
Reason given: Terminated due to low accrual in Cohort B. (Accrual goal for Cohort A was met.)
Key facts
- Where
- Seattle, United StatesSee the 2 sites
Where in United States
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesNo longer taking part
- ProCure Proton Therapy Center-SeattleSeattle, United StatesNo longer taking part
Trial details
- Who runs it
- University of Washington
- Trial code
- NCT02881554
- Record updated
- 29 October 2025
- Original description
This pilot trial studies how well single photon emission computed tomography (SPECT)/computed tomography (CT) with technetium Tc-99m sulfur colloid works in measuring liver function in patients with liver cancer that has or has not spread to other place in the body who are undergoing radiation therapy or surgery. Diagnostic procedures, such as sulfur colloid SPECT/CT scans, may measure normal liver tissue before, during and after treatment and help doctors plan better treatment for liver cancer patients.Read full original descriptionShow less
Functional Liver Imaging With Sulfur Colloid SPECT/CT in Primary and Metastatic Liver Cancer Patients Receiving Liver-Directed Treatment: A Pilot Study
This pilot trial studies how well single photon emission computed tomography (SPECT)/computed tomography (CT) with technetium Tc-99m sulfur colloid works in measuring liver function in patients with liver cancer that has or has not spread to other place in the body who are undergoing radiation therapy or surgery. Diagnostic procedures, such as sulfur colloid SPECT/CT scans, may measure normal liver tissue before, during and after treatment and help doctors plan better treatment for liver cancer patients.
Inclusion: Patients with a diagnosis of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, or metastatic liver cancer planned to receive definitive doses of radiation or surgical resection are eligible; Measurable hepatic disease and/or presence of vascular tumor thrombosis; Diagnostic CT or magnetic resonance imaging (MRI) scan within 2 months of study entry; There are no limits on prior therapy; patients are allowed to have prior systemic therapy, radiation therapy, radiofrequency ablation, catheter-based therapies, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; Ability to understand and the willingness to sign a written informed consent document.
Exclusion: Patients unable to tolerate a SPECT/CT 99mTc-SC scan; Patients who are not planning to adhere to the required follow up schedule as outlined in this protocol; Pregnant women; Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; Patients unable to provide informed consent.